MarginsXMarginsX
Home › Markets › Health Care › LGND

Ligand Pharmaceuticals Incorporated (LGND)

LGND trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$301.71
-2.29% on the day
Market cap
$6.0B
Mid cap
Revenue · 2025
$268.1M
+60.4% on 2024
Net income · 2025
$124.5M
46.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/0000886163-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLGND on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000886163
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$268.1M
Net income$124.5M
Operating income$41.0M
Net margin46.4%
Operating margin15.3%
Revenue growth+60.4%
Cash$174.9M
Total assets$1.6B
P/E (computed)48.5×
P/S (computed)22.5×

Warning signs

Cash runway
Cash-flow positive
$56.0M cash at September 30, 2026
Share count, 1 year
+1.6%
2025-11-04 to 2026-10-27 · +14.7% over 3 years
Going-concern doubt
No
10-Q filed October 30, 2026
Insider net buying, 12 months
-$33.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-30
Cash and burn$56.0M cash; operating cash flow $22.8M a quarter.Report 2026-09-30
Shares outstanding20,002,986 (2026-10-27); 19,681,720 a year earlier; 17,435,958 three years earlier.Cover page 2026-10-27
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-27
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $33.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$78.7M-$28.5M-$27.6M$56.0M$1.1B$253.8M10-Q 2026-10-30
Q2 2026
2026-06-30
$63.7M$48.5M$24.0M$1.0B$1.1B$290.5M10-Q 2026-08-07
Q1 2026
2026-03-31
$51.7M-$13.3M$48.7M$115.1MNo debt tags$274.5M10-Q 2026-05-08
Q4 2025
2025-12-31
$59.7M$44.8M$45.9M$174.9MNo debt tags$268.1M10-K 2026-02-27
Q3 2025
2025-09-30
$115.5M$117.3M$13.1M$139.4MNo debt tags$251.2M10-Q 2026-10-30
Q2 2025
2025-06-30
$47.6M$4.8M$15.8M$67.7MNo debt tags$187.6M10-Q 2026-08-07
Q1 2025
2025-03-31
$45.3M-$42.5M-$25.4M$48.0MNo debt tags$181.5M10-Q 2026-05-08
Q4 2024
2024-12-31
$42.8M-$31.1M$28.5M$72.3MNo debt tags$167.1M10-K 2026-02-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-02-27
Latest annual report10-K2026-02-27
Latest quarterly / interim10-Q2026-10-30
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-05-18

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.8%
1 month+1.7%
3 months+6.9%
Year to date+63.3%
1 year+53.4%
From 52-week high-4.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GRFSGrifols S.A.$8.73+0.46%$6.0B
SUPNSupernus Inc.$28.83-2.99%$6.0B
MIRMMirum Pharmaceuticals Inc.$91.58-2.56%$6.0B
ARWRArrowhead Pharmaceuticals Inc.$44.21-7.47%$6.2B
BLTEBelite Bio Inc$162.56-1.09%$6.5B
MANEVeradermics Incorporated$128.05-1.24%$5.4B
ERASErasca Inc.$15.11-3.51%$5.3B
PTCTPTC Therapeutics Inc.$60.97-3.97%$5.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier